GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangsu Lianhuan Pharmaceutical Co Ltd (SHSE:600513) » Definitions » ROC %

Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) ROC % : 7.57% (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Jiangsu Lianhuan Pharmaceutical Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Jiangsu Lianhuan Pharmaceutical Co's annualized return on capital (ROC %) for the quarter that ended in Mar. 2024 was 7.57%.

As of today (2024-05-26), Jiangsu Lianhuan Pharmaceutical Co's WACC % is 8.03%. Jiangsu Lianhuan Pharmaceutical Co's ROC % is 7.83% (calculated using TTM income statement data). Jiangsu Lianhuan Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Jiangsu Lianhuan Pharmaceutical Co ROC % Historical Data

The historical data trend for Jiangsu Lianhuan Pharmaceutical Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Lianhuan Pharmaceutical Co ROC % Chart

Jiangsu Lianhuan Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.55 10.21 9.93 10.11 7.80

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.37 7.76 6.59 9.35 7.57

Jiangsu Lianhuan Pharmaceutical Co ROC % Calculation

Jiangsu Lianhuan Pharmaceutical Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=198.436 * ( 1 - 13.54% )/( (2099.879 + 2299.198)/ 2 )
=171.5677656/2199.5385
=7.80 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2714.939 - 490.331 - ( 330.647 - max(0, 1243.829 - 1368.558+330.647))
=2099.879

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2855.702 - 449.622 - ( 281.38 - max(0, 1246.521 - 1353.403+281.38))
=2299.198

Jiangsu Lianhuan Pharmaceutical Co's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=221.144 * ( 1 - 20.57% )/( (2299.198 + 2340.283)/ 2 )
=175.6546792/2319.7405
=7.57 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2855.702 - 449.622 - ( 281.38 - max(0, 1246.521 - 1353.403+281.38))
=2299.198

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2829.973 - 371.237 - ( 237.127 - max(0, 1184.031 - 1302.484+237.127))
=2340.283

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangsu Lianhuan Pharmaceutical Co  (SHSE:600513) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Jiangsu Lianhuan Pharmaceutical Co's WACC % is 8.03%. Jiangsu Lianhuan Pharmaceutical Co's ROC % is 7.83% (calculated using TTM income statement data). Jiangsu Lianhuan Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Jiangsu Lianhuan Pharmaceutical Co ROC % Related Terms

Thank you for viewing the detailed overview of Jiangsu Lianhuan Pharmaceutical Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Business Description

Traded in Other Exchanges
N/A
Address
No. 21 Wenfeng Road, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225009
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs.
Executives
Chu Qing Song senior management
Xia Chun Lai Director
Pan He Ping Directors, senior managers
Niu Ben senior management
Wu Wen Ge Director
Zhu Yong Jun senior management
Qian Zhen Hua Director
Shen Yi senior management
Huang Wen Tao senior management
Zhou Jun senior management
Tu Bin senior management
Qin Xiong Jian senior management

Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Headlines

No Headlines